A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anita Scheuber, MD, PhD
Nimbus Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Liverpool Hospital
Liverpool, New South Wales, Australia
Aflah Roohullah, MD; PHDRecruiting - Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia
Ganessan Kichenadasse, MD; PHDRecruiting
- Princess Margaret Cancer Center
Toronto, Ontario, Canada
Eric Chen, MD; PHDRecruiting
- Hôpital Saint-Antoine - Assistance Publique-Hopitaux de Paris (ap-Hp)
Paris, France
Thierry Andre, MDRecruiting - Centre Hospitalier Universitaire (chu) de Poitiers
Poitiers, France
David Tougeron, MDRecruiting
- Start Dublin
Dublin, Ireland
Austin Duffy, MDRecruiting
- Start Lisbon
Lisbon, Portugal
Andre Mansinho, MDRecruiting
- Start Barcelona
Barcelona, Spain
Roberto Martin Huertas, MDRecruiting - Hospital Clinico San Carlos
Madrid, Spain
Jorge Bartolome, MDRecruiting
- Sarah Cannon Research Institute Uk
London, United Kingdom
Elisa Fontana, MDRecruiting - the Christie Nhs Foundation Trust Uk
Manchester, United Kingdom
Donna Graham, MDRecruiting
- Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
Josef Lenz, MD; FACPRecruiting - University of Chicago Medicine
Chicago, Illinois, United States
John Moroney, MDRecruiting - University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky, United States
Rebecca Redman, MDRecruiting - Cayuga Cancer Center
Ithaca, New York, United States
Terminated - Levine Cancer Center
Charlotte, North Carolina, United States
R. Wendel Naumann, MDRecruiting - Atrium Health Wake Forest Baptist Center
Winston-Salem, North Carolina, United States
R. Wendel Naumann, MDRecruiting - Taylor Cancer Research Center
Maumee, Ohio, United States
John Nemunaitis, MDRecruiting - Brown University Health
Providence, Rhode Island, United States
Benedito Carneiro Filho, MD; MS; PhDRecruiting - Prisma Health Cancer Institute - Multidisciplinary Center
Greenville, South Carolina, United States
William Edenfield, MDRecruiting - University of Virginia Emily Couric Clinical Cancer Center
Charlottesville, Virginia, United States
Matthew Reilley, MDRecruiting - Virginia Cancer Specialists, P.C. - Fairfax
Fairfax, Virginia, United States
Alexander Spira, MD;PhD;FACPRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2025
- Primary completion
- 31 Oct 2031
- Completion
- 31 Dec 2031
- Last update posted
- 6 May 2026
- Registered enrollment
- 134
- Registry id
- NCT06898450
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.